As U.S. prices remain elevated despite larger-than-usual inventories, the gap in U.S. Comex futures over those on the LME has fluctuated between $500 and $1,500 since Trump announced a probe into ...

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...